Clinical Trial Update: Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of an anti-CD22 CAR-T therapy for CD19-refractory or resistant lymphomas, including diffuse large B-cell lymphoma, follicular lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Anti-CD22 CAR-T therapy

Snippet

Sponsor: Xinqiao Hospital of Chongqing | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Status: UNKNOWN